Actively Recruiting
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy
Led by Kaohsiung Medical University · Updated on 2026-01-22
552
Participants Needed
1
Research Sites
114 weeks
Total Duration
On this page
Sponsors
K
Kaohsiung Medical University
Lead Sponsor
K
Kaohsiung Veterans General Hospital.
Collaborating Sponsor
AI-Summary
What this Trial Is About
(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.
CONDITIONS
Official Title
Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults with Helicobacter pylori infection
You will not qualify if you...
- Known allergy or hypersensitivity to the study drugs
- History of stomach surgery
- Severe liver cirrhosis or uremia
- History of cancer within the past five years
- Pregnant or breastfeeding women
- Currently taking atazanavir sulfate or rilpivirine hydrochloride
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan, 807
Actively Recruiting
Research Team
D
Deng-Chyang Wu, MD, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here